Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (12): 1189-1193    DOI: 10.19485/j.cnki.issn2096-5087.2022.12.001
  标准·方案·指南 本期目录 | 过刊浏览 | 高级检索 |
系统性红斑狼疮患者疫苗接种专家共识
浙江省预防医学会风湿病预防与控制专业委员会,浙江 杭州 310003
Expert consensus on vaccination among adult patients withsystemic lupus erythematosus
Rheumatic Disease Prevention and Control Committee, Zhejiang Preventive Medical Association, Hangzhou, Zhejiang 310003, China
全文: PDF(783 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 系统性红斑狼疮(SLE)是慢性自身免疫性疾病,感染是最常见的并发症和死亡原因之一。接种疫苗是SLE患者预防感染的有效手段。浙江省预防医学会风湿病预防与控制专业委员会针对SLE患者接种疫苗预防感染、疫苗种类、接种时机、有效性和安全性以及SLE治疗药物对接种的影响等问题形成此专家共识,以指导风湿科医生和预防接种人员为SLE患者规范接种疫苗,预防感染,提高SLE患者生命质量。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 系统性红斑狼疮预防接种感染共识    
Abstract:Systemic lupus erythematosus (SLE) is a chronic autoimmune disease and infection is one of the most common complications and death causes of SLE. Vaccination is an effective tool for prevention of infections among SLE patients. This expert consensus was achieved by the Rheumatic Disease Prevention and Control Committee, Zhejiang Preventive Medical Association on the prevention of infections with vaccines, types of vaccines, vaccination timing, efficacy and safety of vaccines and impact of therapeutic agents for SLE on vaccinations to guide the rheumatologists and vaccination professionals for scientific and standardized vaccinations among SLE patients, so as to prevent infection and improve quality of life among SLE patients.
Key wordssystemic lupus erythematosus    vaccination    infection    consensus
收稿日期: 2022-10-09      修回日期: 2022-10-24      出版日期: 2022-12-10
中图分类号:  R593.24  
  R186  
通信作者: 杨旭燕,E-mail:hangzhouyxy@zju.edu.cn;胡昱,E-mail:yhu@cdc.zj.cn   
引用本文:   
. 系统性红斑狼疮患者疫苗接种专家共识[J]. 预防医学, 2022, 34(12): 1189-1193.
链接本文:  
https://www.zjyfyxzz.com/CN/Y2022/V34/I12/1189
[1] ZHU T Y,TAM L S,LEE V W,et al.The impact of flare on disease costs of patients with systemic lupus erythematosus[J].Arthritis Rheum,2009,61(9):1159-1167.
[2] ILLESCAS-MONTES R,CORONA-CASTRO C C,MELGUIZO-RODRÍGUEZ L,et al.Infectious processes and systemic lupus erythematosus[J].Immunology,2019,158(3):153-160.
[3] LIU Z,DAVIDSON A.Taming lupus-a new understanding of pathogenesis is leading to clinical advances[J].Nat Med,2012,18(6):871-882.
[4] GATTO M,ZEN M,IACCARINO L,et al.New therapeutic strategies in systemic lupus erythematosus management[J].Nat Rev Rheumatol,2019,15(1):30-48.
[5] RIGANTE D,ESPOSITO S.Infections and systemic lupus erythematosus:binding or sparring partners?[J].Int J Mol Sci,2015,16(8):17331-17343.
[6] PAN Q,LIU Z,LIAO S,et al.Current mechanistic insights into the role of infection in systemic lupus erythematosus[J/OL].Biomed Pharmacother,2019,117[2022-10-24].https://doi.org/10.1016/j.biopha.2019.109122.
[7] RIGANTE D,MAZZONI M B,ESPOSITO S.The cryptic interplay between systemic lupus erythematosus and infections[J].Autoimmun Rev,2014,13(2):96-102.
[8] WU X Y,YANG M,XIE Y S,et al.Causes of death in hospitalized patients with systemic lupus erythematosus:a 10-year multicenter nationwide Chinese cohort[J].Clin Rheumatol,2019,38(1):107-115.
[9] MOK C C.Herpes zoster vaccination in systemic lupus erythematosus:the current status[J].Hum Vaccin Immunother,2019,15(1):45-48.
[10] DAVID E, BELOT A, LEGA J C, et al.Human papillomavirus and systemic lupus erythematosus[J].Rev Med Interne, 2021, 42(7):498-504.
[11] SUN F F,CHEN Y,WU W L,et al.Varicella zoster virus infections increase the risk of disease flares in patients with SLE:a matched cohort study[J/OL].Lupus Sci Med,2019,6(1)[2022-10-24].http://dx.doi.org/10.1136/lupus-2019-000339.
[12] FURER V,RONDAAN C,HEIJSTEK M W,et al.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J].Ann Rheum Dis,2020,79(1):39-52.
[13] CORDEIRO I,DUARTE A C,FERREIRA J F,et al.Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the portuguese society of rheumatology[J].Acta Reumatol Port,2016,41(2):112-130.
[14] AYTAC M B,KASAPCOPUR O,ASLAN M,et al.Hepatitis B vaccination in juvenile systemic lupus erythematosus[J].Clin Exp Rheumatol,2011,29(5):882-886.
[15] MOK C C,HO L Y,FONG L S,et al.Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus:a case-control study[J].Ann Rheum Dis,2013,72(5):659-664.
[16] BOMBARDIER C,GLADMAN D D,UROWITZ M B,et al.Derivation of the SLEDAI.A disease activity index for lupus patients.The Committee on Prognosis Studies in SLE[J].Arthritis Rheum,1992,35(6):630-640.
[17] COOK R J,GLADMAN D D,PERICAK D,et al.Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity[J].J Rheumatol,2000,27(8):1892-1895.
[18] GLADMAN D D,UROWITZ M B,KAGAL A,et al.Accurately describing changes in disease activity in systemic lupus erythematosus[J].J Rheumatol,2000,27(2):377-379.
[19] YEE C S,ISENBERG D A,PRABU A,et al.BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000[J].Ann Rheum Dis,2008,67(6):873-876.
[20] HOLVAST A,HUCKRIEDE A,WILSCHUT J,et al.Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease[J].Ann Rheum Dis,2006,65(7):913-918.
[21] LIPNICK R N,KARSH J,STAHL N I,et al.Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives[J].J Rheumatol,1985,12(6):1118-1121.
[22] KURUMA K A,BORBA E F,LOPES M H,et al.Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus[J].Lupus,2007,16(5):350-354.
[23] HARPAZ R,ORTEGA-SANCHEZ I R,SEWARD J F.Prevention of herpes zoster:recommendations of the Advisory Committee on Immunization Practices(ACIP)[J].MMWR Recomm Rep,2008,57(5):1-30.
[24] FURER V,EVIATAR T,ZISMAN D,et al.Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population:a multicentre study[J].Ann Rheum Dis,2021,80(10):1330-1338.
[25] GARG M,MUFTI N,PALMORE T N,et al.Recommendations and barriers to vaccination in systemic lupus erythematosus[J].Autoimmun Rev,2018,17(10):990-1001.
[26] HUA C, BARNETCHE T, COMBE B, et al.Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta- analysis[J].Arthritis Care Res,2014,66:1016-1026.
[27] RASMUSSEN S L,FUURSTED K,NIELSEN K A,et al.Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status[J].Scand J Rheumatol,2020,49(5):353-360.
[28] HEIJSTEK M W,SCHERPENISSE M,GROOT N,et al.Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis:a prospective controlled observational cohort study[J].Ann Rheum Dis,2014,73(8):1500-1507.
[29] ABU-SHAKRA M,PRESS J,VARSANO N,et al.Specific antibody response after influenza immunization in systemic lupus erythematosus[J].J Rheumatol,2002,29(12):2555-2557.
[30] PAPPAIOANOU M,FISHBEIN D B,DREESEN D W,et al.Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine[J].N Engl J Med,1986,314(5):280-284.
[31] CHATHAM W W,WALLACE D J,STOHL W,et al.Effect of belimumab on vaccine antigen antibodies to influenza,pneumococcal,and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial[J].J Rheumatol,2012,39(8):1632-1640.
[32] BINGHAM C O 3rd,LOONEY R J,DEODHAR A,et al.Immunization responses in rheumatoid arthritis patients treated with rituximab:results from a controlled clinical trial[J].Arthritis Rheum,2010,62(1):64-74.
[33] 浙江省卫生健康委员会.浙江省疫苗接种方案(2021年版)[EB/OL].[2022-10-24].https://wsjkw.zj.gov.cn/art/2021/10/19/art_1229560650_2369617.html.
[34] PAPP K A,HARAOUI B,KUMAR D,et al.Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies[J].J Cutan Med Surg,2019,23(1):50-74.
[35] LOPEZ A,MARIETTE X,BACHELEZ H,et al.Vaccination recommendations for the adult immunosuppressed patient:a systematic review and comprehensive field synopsis[J].J Autoimmun,2017,80:10-27.
[1] 倪赛丽, 唐金陵, 舒强, 朱善宽. 祖孙三代家庭队列研究适宜技术专家共识[J]. 预防医学, 2026, 38(1): 1-9.
[2] 张俊杰, 罗超, 姜立坤, 张慧颖. 2015—2024年哈尔滨市百日咳流行特征分析[J]. 预防医学, 2025, 37(9): 941-944.
[3] 苏德华, 陈向阳, 李君, 赵丽娜, 张鹤美, 朱婷婷, 胡文雪, 赖江宜. 温州市新报告HIV/AIDS病例抗病毒治疗及时性分析[J]. 预防医学, 2025, 37(8): 804-808.
[4] 查杰, 王达. 肠道菌群与非感染性胃肠炎的双向孟德尔随机化研究[J]. 预防医学, 2025, 37(8): 814-817.
[5] 冷雪, 傅淑琴, 舒纪为, 谭启龙, 李科峰. 舟山市带状疱疹首诊病例特征分析[J]. 预防医学, 2025, 37(7): 701-704.
[6] 孙玲, 刘元青, 刘新光, 张楠, 温婵, 郝建宗, 李梅. 河北省某儿童医院住院患儿多重耐药菌耐药性分析[J]. 预防医学, 2025, 37(6): 616-621.
[7] 白茂潮, 李芬, 地力努尔·吐尔逊, 热米拉·热扎克, 王岩. HPV感染女性焦虑症状的影响因素分析[J]. 预防医学, 2025, 37(6): 573-577,582.
[8] 陈家烨, 胡昱. 浙江省社区卫生服务中心预防接种人员流动性调查[J]. 预防医学, 2025, 37(5): 536-540.
[9] 罗秀兰, 郑永韬, 倪梦姣, 鲁潮, 徐婷燕, 翁绩燕, 来芬华. 一起带状疱疹病例引起的医院水痘暴发疫情调查[J]. 预防医学, 2025, 37(5): 490-493.
[10] 张超, 沈建勇, 罗小福, 刘艳, 韩利萍. 2007—2023年湖州市流行性乙型脑炎流行特征[J]. 预防医学, 2025, 37(4): 386-389.
[11] 王燕, 罗鹏. 湖州市某医院急性呼吸道感染病例常见病原体感染特征分析[J]. 预防医学, 2025, 37(3): 300-303.
[12] 王苓, 许珂, 张兴亮, 黄思超, 李西婷, 陈珺芳. 2022年杭州市新报告HIV/AIDS病例感染特征分析[J]. 预防医学, 2025, 37(2): 123-129.
[13] 徐青华, 杨涛. 常山县血吸虫病综合治理策略及工作回顾[J]. 预防医学, 2025, 37(2): 212-216.
[14] 董振鑫, 罗小福, 李军伟, 张子喆, 沈建勇. 湖州市鼠形动物自然感染病原体监测结果[J]. 预防医学, 2025, 37(11): 1170-1174.
[15] 李依窈, 李小菊, 申小颖, 张宪琦, 赵莉, 张玉涵, 汪欣梦. 老年人接种流行性感冒疫苗的影响因素分析[J]. 预防医学, 2025, 37(1): 31-35.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed